Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant
Just Received European Green Light For Skin Disorder
It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.
You may also be interested in...
Weeks after FDA authorized emergency use of its antibody bamlanivimab, Lilly’s RA drug Olumiant can be used to shorten recovery time for hospitalized COVID-19 patients in the US. Authorizations are being pursued elsewhere as well.
Arena said its S1P receptor modulator missed the primary endpoint in a Phase IIb trial but data from patients with uninterrupted treatment justify moving etrasimod into a pivotal program.
Take a brief audio tour around the main biopharma industry events of the past week, as brought to you by Scrip's global team, in this podcast version of Five Must-Know Things.